CorInnova

CorInnova is pioneering a disruptive approach to mechanical circulatory support with its minimally invasive, non-blood contacting cardiac assist device. Backed by a lead investment from the Wellcome Trust, the company targets the acute heart failure market, seeking to treat patients unsuitable for existing blood-contacting devices. Its technology promises to eliminate risks like thrombosis and stroke, potentially expanding the addressable market to $5 billion. CorInnova is in the preclinical/development stage, building a strong advisory board and securing non-dilutive grant funding.

Minimally invasive, implantable cardiac assist system for Direct Cardiac Compression (DCC). The device is collapsible, non-blood contacting, and uses external pneumatic actuation to synchronously compress the heart, increasing cardiac output without the risks of thrombosis or need for anticoagulants.

CorInnova competes in the acute mechanical circulatory support market against established devices like Abiomed's Impella, Getinge/MAQUET's IABP and Cardiohelp system, and Abbott's CentriMag. Its primary competitive advantage is the non-blood contacting design, which aims to avoid the major complications (bleeding, thrombosis, stroke) associated with these incumbent technologies, targeting patients currently without a viable device option.